Enhanced sensitivity HP-gas MRI/PET Dual Modality Imaging for Alzheimer's disease detection.

医学成像技术在各种疾病的早期诊断和管理以及临床研究和药物开发中发挥着至关重要的作用。医学成像系统的不断发展极大地提高了我们对身体组织和过程的可视化能力，使我们能够更准确地检测医疗状况。然而，个性化医疗的最新趋势要求采用针对特定器官或疾病定制的器官特异性成像工具进行精确诊断的新方法。双模态成像是这一方法不可或缺的一部分，因为它提供了基于对齐的形态和功能数据的免费视觉和定量信息，因此提供了最高的疗效和诊断能力。影响最大的领域之一是阿尔茨海默病（AD），其中需要精确成像来准确识别特定AD生物标志物的组合。这有希望预测痴呆症的风险患者的未来发展，并使阿尔茨海默病的病理诊断在早期阶段时，可用的治疗是最有效的。本研究的总体目标是开发一种将联合收割机脑专用正电子发射断层扫描（PET）与磁共振成像（MRI）相结合的成像系统，用于精确的生物标记物引导的AD治疗。PET/MRI系统将PET的代谢和分子信息与MRI的结构和功能信息相结合，具有独特的优势，可提高AD的早期诊断和鉴别诊断。所提出的PET/MRI技术的商业化和临床应用将克服AD检测、干预和预防的“一刀切”方法，并将在加拿大和全球范围内推动AD管理领域超越当前的护理标准。

Medical imaging technologies play a crucial role in early diagnosis and management of a variety of diseases, aswell as in clinical research and drug development. Continued developments of medical imaging systems havevastly improved our ability to visualize body tissues and processes, enabling more accurate detection ofmedical conditions. However, recent trends for personalized medicine call for new approaches in precisiondiagnostics with organ-specific imaging tools customized for particular organs or diseases. Dual-modalityimaging is an integral part of this approach as it offers complimentary visual and quantitative information thatis based on aligned morphological and functional data and therefore provides the highest efficacy anddiagnostic capability.One of the biggest areas of impact is Alzheimer's Disease (AD) where precision imaging is required foraccurate identification of a combination of specific AD biomarkers. This holds a promise to predict the futuredevelopment of dementia in patients at risk and to enable the diagnosis of Alzheimer's pathology at the earlystages when available treatments are maximally effective. It is also of a high importance to stratify cohort ofpatients for clinical trials with AD modifying therapies and for clinical neuroscience research.The overarching goal of this proposal is to develop an imaging system that will combine brain-dedicatedPositron Emission Tomography (PET) with Magnetic Resonance Imaging (MRI) for precisionbiomarker-guided medicine in AD. The proposed PET/MRI system will have some unique advantages toimprove early and differential diagnosis of AD through combining the metabolic and molecular informationfrom PET and structural, functional information from MRI. The commercialization and clinical use of theproposed PET/MRI technology will overcome "one-size-fits-all" approach for AD detection, intervention andprevention, and will advance the field of AD management beyond the current standard of care in Canada, andglobally.